Safety and efficacy of autoantigen‐specific therapy with 2 doses of alum‐formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial

Objective Treatments have failed to delay or stop the autoimmune process, preceding onset of type 1 diabetes. We investigated if autoantigen‐specific treatment with alum‐formulated glutamate decarboxylase (GAD‐Alum) was safe and affected progression to type 1 diabetes in children with islet autoimmu...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Pediatric diabetes Ročník 19; číslo 3; s. 410 - 419
Hlavní autori:	Elding Larsson, Helena, Lundgren, Markus, Jonsdottir, Berglind, Cuthbertson, David, Krischer, Jeffrey
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Former Munksgaard John Wiley & Sons A/S 01.05.2018 John Wiley & Sons, Inc
Predmet:	Aluminum sulfate Autoantibodies Autoimmunity Children Clinical Medicine Clinical trials Diabetes Diabetes mellitus Diabetes mellitus (insulin dependent) Endocrinology and Diabetes Endokrinologi och diabetes GAD‐Alum Glucose Glucose tolerance Glutamate decarboxylase Hematology Immunological tolerance Insulin Insulinoma Intravenous administration Klinisk medicin Medical and Health Sciences Medicin och hälsovetenskap Neuroendocrine tumors Pediatrics Pediatrik prevention Safety Thyroid type 1 diabetes type 1 diabetes autoimmunity GAD-Alum prevention
ISSN:	1399-543X, 1399-5448, 1399-5448
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!